Table 3.
Venous Thromboembolism and Bleeding Outcomes
| Bridging | No Bridging | ||||||
|---|---|---|---|---|---|---|---|
| Study | Follow-up Duration | Venous thromboembolism/ Procedures, n (%) | Major Bleeding/ Procedures, n (%) | Any Bleeding ||/ Procedures, n (%) | Venous thromboembolism/ Procedures, n (%) | Major Bleeding/ Procedures, n (%) | Any Bleeding ||/ Procedures, n (%) |
| Ahmed, 201021 | 8 weeks | 0/12 (0) | NA | 1/12 (8.3) | 0/5 (0) | NA | 0/5 (0) |
| Bajkin, 200922* | 30d | 0/19 (0) | NA | not clear | - | - | - |
| Birnie, 201323* | not clear | 0/16 (0) | NA | not clear | - | - | - |
| Breen, 201624 | 30d | 0/29 (0) | not clear | 6/29 (20.7) | - | - | - |
| Burbury, 201125* | 6 weeks | - | - | - | 0/39 (0) | not clear | not clear |
| Clark, 20157 | 30d | 0/555 (0) | 12/555 (2.2) | 15/555 (2.7) | 3/1257 (0.2) | 2/1257 (0.2) | 2/1257 (0.2) |
| Constans, 200742* | 90d | 0/10 (0) | not clear | not clear | - | - | - |
| Douketis, 200520 | until INR 2–3 | NA | 0/21 (0) | 0/21 (0) | - | - | - |
| Dunn, 200726 | 28d | 1/96 (1.0) | not clear | not clear | - | - | - |
| Eisele, 201227* | not clear | 0/69 (0) | NA | not clear | - | - | - |
| Fernandez, 200928* | 30d | 0/24 (0) | not clear | not clear | 0/14 (0) | 0/14 (0) | 0/14 (0) |
| Garcia, 200829 | 30d | 0/22 (0) | not clear | not clear | 2/179 (1.1) | 0/179 (0) | 0/179 (0) |
| Hammerstingl, 200930* | not clear | 0/10 (0) | 0/10 (0) | 0/10 (0) | - | - | - |
| Hwang, 201731* | 30d | 0/34 (0) | not clear | not clear | - | - | - |
| Jaffer, 200532 | 30d | 0/18 (0) | 1/18 (5.6) | 1/18 (5.6) | - | - | - |
| Klamroth, 201012 | 28d | 0/63 (0) | 0/63 (0) † | 0/63 (0) † | - | - | - |
| Majluf-Cruz, 201133 | not clear | 2/152 (1.3) | 4/152 (2.6) | 26/152 (17.1) | - | - | - |
| Malato, 201034 | 30d | 2/45 (4.4) | 1/45 (2.2) | 1/45 (2.2) | - | - | - |
| McBane, 201013 | 90d | 4/342 (1.2) † | 9/342 (2.6) † | 24/342 (7.0) † | 3/152 (2.0) † | 1/152 (0.7) † | 3/152 (2.0) † |
| Pengo, 200914 | 30d | 2/210 (1.0) | 1/210 (0.5) † | 9/210 (4.3) † | - | - | - |
| Saccullo, 201235 | 30d | 2/52 (3.8) | not clear | not clear | - | - | - |
| Santamaria, 201336* | 90d | 0/10 (0) | not clear | not clear | - | - | - |
| Sjögren, 201718 | 30d | 10/1331 (0.8) | NA | 10/1331 (0.8) | 5.5/1331 (0.4) ‡ | NA | 2.1/1331 (0.2) ‡ |
| Skeith, 201237 | 90d | 2/152 (1.3) | 2/152 (1.3) | 6/152 (3.9) | 2/482 (0.4) | 8/482 (1.6) | 16/482 (3.3) |
| Spyropoulos, 200438 | 60d | 0/45 (0) | 0/45 (0) | 2/45 (4.4) | - | - | - |
| Spyropoulos, 200639* | 30d | 0/22 (0) § | not clear | not clear | - | - | - |
| Wilson, 200140 | 90d | 0/26 (0) | 0/26 (0) | 0/26 (0) | - | - | - |
| Wiszniewsky, 201141 | 180d | 0/63 (0) | 0/63 (0) | 13/63 (20.6) | - | - | - |
Abbreviations: NR, not available because outcome was not assessed in study.
these studies did not specifically report venous thromboembolism outcomes by indication for anticoagulation (i.e. patients with previous venous thromboembolism), but were included because the number of outcome events was 0 for all indications
personal communication by the authors
patients not receiving bridging anticoagulation were propensity score matched and weighted to equal the number of patients who received bridging
the number of venous thromboembolic events in subgroup of patients with a previous venous thromboembolism could only be identified in the 22 patients who received unfractionated heparin
includes major bleeding and any other bleeding outcome that was specifically reported for patients with previous venous thromboembolism